NDAORALTABLET
Approved
Apr 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIRADON (anisindione) is an oral indandione anticoagulant approved in 1957 for thromboembolic disorders. It works as a vitamin K antagonist to inhibit clotting factor synthesis. It is a legacy small-molecule therapeutic in the late stages of its commercial lifecycle.
LOE Approaching
This legacy product is approaching loss of exclusivity with minimal linked job openings, indicating a small, stable team focused on maintenance rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MIRADON offers minimal career growth potential; it is a legacy maintenance product with zero linked job openings and declining commercial relevance. Professionals assigned to this brand should view it as a consolidation or transition role rather than a launch or growth opportunity.
Brand Manager (legacy products)Medical Science Liaison
Worked on MIRADON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.